REVIEW PAPER
Suppressor genes as molecular markers of colorectal cancer – a review of the latest reports
1
Department of Surgical Medicine with the Laboratory of Medical Genetics,, Institute of Medical Sciences, Jan Kochanowski University, Kielce, Poland
2
Department of Cardiovascular Disease Prevention and Pharmacology, Institute of Health Sciences, Jan Kochanowski University, Kielce, Poland
3
Department of Clinic General Oncological and Endocrinological Surgery, Regional Hospital, Kielce, Poland
Submission date: 2019-11-21
Final revision date: 2020-02-14
Acceptance date: 2020-03-07
Publication date: 2020-03-31
Medical Studies 2020;36(1):35-45
KEYWORDS
TOPICS
ABSTRACT
Suppressor gene research is one of the main current trends in modern cancer research. Oncogenesis, including colorectal cancer (CRC), is a process strictly dependent on the proper functioning of the suppressor genes and their proteins. The molecular genetic studies of hereditary cases and sporadic forms of cancer conducted for several years have revealed that a significant feature of the occurrence and progression of neoplastic changes is silencing of the expression of tissue-specific suppressor genes. Restoring the proper activity of the respective suppressor proteins plays a key role in anti-cancer prevention and gives hope for the development of effective personalised therapy. This review presents the latest reports on the molecular mechanisms regulating the expression, activity, and function of suppressor genes, which were silenced in tissues and cell lines of colorectal cancer, and restoration of their correct expression inhibited the proliferation and invasion of CRC cells.
REFERENCES (59)
1.
McFerran E, O’mahony JF, Fallis R, Mcvicar D, Zauber AG, Kee F. Evaluation of the effectiveness and cost-effectiveness of personalized surveillance after colorectal adenomatous polypectomy. Epidemiol Rev 2017; 39: 148-160.
2.
Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol 2019; 14: 89-103.
7.
Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002; 3: 11-20.
8.
Lai PS, Cheah PY, Kadam P, Chua CLM, Lie DKH, Li HH, Eu KW, Seow-Choen F, Lee AS. Overexpression of RB1 transcript is significantly correlated with 13q14 allelic imbalance in colorectal carcinomas. Int J Cancer 2006; 119: 1061-1066.
9.
Kopczyński P, Krawczyński MR. The role of oncogenes and tumor suppressor genes in oncogenesis. Now Lek 2012; 81: 679-681.
10.
Slattery ML, Mullany LE, Wolff RK, Sakoda LC, Samowitz WS, Herrick JS. The p53-signaling pathway and colorectal cancer: interactions between downstream p53 target genes and miRNAs. Genomics 2019; 111: 762-771.
11.
Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer 2017; 83: 258-265.
12.
Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, Fish P, Harsha B, Hathaway C, Jupe SC, Kok CY, Noble K, Ponting L, Ramshaw CC, Rye CE, Speedy HE, Stefancsik R, Thompson SL, Wang S, Ward S, Campbell PJ, Forbes SA. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res 2019; 47: D941-D947.
13.
Manoharan V, Karunanayake EH, Tennekoon KH, De Silva S, Imthikab AIA, De Silva K, Angunawela P, Vishwakula S, Lunec J. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients. BMC Cancer 2020; 20: 72.
14.
Zhang G, Xu Q, Wang Z, Sun L, Lv Z, Liu J, Xing C, Yuan Y. P53 protein expression affected by TP53 polymorphism is associated with the biological behavior and prognosis of low rectal cancer. Oncol Lett 2019; 18: 6807-6821.
15.
Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
16.
Zhao R, Choi BY, Lee M-H, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16 INK4a) in cancer. EBioMedicine 2016; 8: 30-39.
17.
Mitomi H, Fukui N, Tanaka N, Kanazawa H, Saito T, Matsuoka T, Yao T. Aberrant p16INK4a methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J Cancer Res Clin Oncol 2010; 136: 323-331.
18.
Barault L, Charon-Barra C, Jooste V, De La Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008; 68: 8541-8546.
19.
Ye X, Mo M, Xu S, Yang Q, Wu M, Zhang J, Chen B, Li J, Zhong Y, Huang Q, Cai C. The hypermethylation of p16 gene exon 1 and exon 2: Potential biomarkers for colorectal cancer and are associated with cancer pathological staging 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. BMC Cancer 2018; 18: 1023.
20.
Aghabozorgi AS, Bahreyni A, Soleimani A, Bahrami A, Khazaei M, Ferns GA, Avan A, Hassanian SM. Role of APC gene mutations in the pathogenesis of colorectal cancer current status and perspectives.pdf. Biochimie 2019; 157: 64-71.
21.
Zhang M, Yang D, Gold B. The Adenomatous Polyposis Coli (APC) mutation spectra in different anatomical regions of the large intestine in colorectal cancer. Mutat Res 2018; 810: 1-5.
22.
Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-850.
23.
Tanneberger K, Pfister AS, Kriz V, Bryja V, Schambony A, Behrens J. Structural and functional characterization of the Wnt inhibitor APC membrane recruitment 1 (Amer1). J Biol Chem 2011; 286: 19204-19214.
24.
Rogacki K. Rola komórkowej ekspresji beta-kateniny i E-kadheryny jako markerów progresji zmian w przewlekłym zapaleniu wątroby typu C. Rozprawa na stopień doktora nauk medycznych. Uniwersytet Medyczny im. K. Marcinkowskiego w Poznaniu 2014.
25.
Hankey W, Frankel WL, Groden J. Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer Metastasis Rev 2018; 37: 159-172.
26.
Brembeck FH, Rosário M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006; 16: 51-59.
27.
Yan R, He L, Li Z, Han X, Liang J, Si W, Chen Z, Li L, Xie G, Li W, Wang P, Lei L, Zhang H, Pei F, Cao D, Sun L, Shang Y. SCFJFK is a bona fide e3 ligase for ING4 and a potent promoter of the angiogenesis and metastasis of breast cancer. Genes Dev 2015; 29: 672-685.
28.
Cui S, Gao Y, Zhang K, Chen J, Wang R, Chen L. The emerging role of inhibitor of growth 4 as a tumor suppressor in multiple human cancers. Cell Physiol Biochem 2015; 36: 409-422.
29.
Chen Y, Huang Y, Hou P, Zhang Z, Zhang Y, Wang W, Sun G, Xu L, Zhou J, Bai J, Zheng J. ING4 suppresses tumor angiogenesis and functions as a prognostic marker in human colorectal cancer. Oncotarget 2016; 7: 79017-79031.
30.
Vizcaíno C, Mansilla S, Portugal J. Sp1 transcription factor: a long-standing target in cancer chemotherapy. Pharmacol Ther 2015; 152: 111-124.
31.
You Q, Wang X, Fu S, Jin X. Downregulated expression of inhibitor of growth 4 (ING4) in advanced colorectal cancers: a non-randomized experimental study. Pathol Oncol Res 2011; 17: 473-477.
32.
You Q, Li H, Liu Y, Xu Y, Miao S, Yao G, Xue Y, Geng J, Jin X, Meng H. MicroRNA-650 targets inhibitor of growth 4 to promote colorectal cancer progression via mitogen activated protein kinase signaling. Oncol Lett 2018; 16: 2326-2334.
33.
Zhao M, Mishra L, Deng CX. The role of TGF-beta/SMAD4 signaling in cancer. Int J Biol Sci 2018; 14: 111-123.
34.
Witkowska M, Smolewski P. Białka z rodziny SMAD: współczesna wiedza na temat ich ekspresji i potencjalnej roli w chorobach nowotworowych. Postep Hig Med Dosw 2014; 68: 301-309.
35.
Liao X, Hao Y, Zhang X, Ward S, Houldsworth J, Polydorides AD, Harpaz N. Clinicopathological characterization of SMAD4-mutated intestinal adenocarcinomas: a case-control study. PLoS One 2019; 14: e0212142.
36.
Lin Z, Zhang L, Zhou J, Zheng J. Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelial-mesenchymal transition. Mol Med Rep 2019; 20: 3735-3745.
37.
Chung Y, Wi YC, Kim Y, Bang SS, Yang JH, Jang K, Min KW, Paik SS. The Smad4/PTEN expression pattern predicts clinical outcomes in colorectal adenocarcinoma. J Pathol Transl Med 2018; 52: 37-44.
38.
Memon A, Lee WK. KLF10 as a tumor suppressor gene and its TGF-beta signaling. Cancers 2018; 10: 161.
39.
Chen GG, Xu H, Lee JFY, Subramaniam M, Leung KL, Wang SH, Chan UP, Spelsberg TC. 15-hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cellsvia a peroxisome proliferator-activated receptor gamma-dependent pathway. Int J Cancer 2003; 107: 837-843.
40.
Roock W De, Vriendt V De, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603.
41.
Kotelevets L, Scott MGH, Chastre E. Targeting PTEN in colorectal cancers. Adv Exp Med Biol 2018; 1110: 55-73.
42.
Roquid KAR, Alcantara KMM, Garcia RL. Identification and validation of mRNA 3’untranslated regions of DNMT3B and TET3 as novel competing endogenous RNAs of the tumor suppressor PTEN. Int J Oncol 2020; 56: 544-558.
43.
Ye L, Jiang WG. Bone morphogenetic proteins in tumour associated angiogenesis and implication in cancer therapies. Cancer Lett 2016; 380: 586-597.
44.
Chen E, Yang F, He H, Li Q, Zhang W, Xing J, Zhu Z, Jiang J, Wang H, Zhao X, Liu R, Lei L, Dong J, Pei Y, Yang Y, Pan J, Zhang P, Liu S, Du L, Zeng Y, Yang J. Alteration of tumor suppressor BMP5 in sporadic colorectal cancer: a genomic and transcriptomic profiling based study. Mol Cancer 2018; 17: 176.
45.
Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer 2015; 113: 365-371.
46.
De Neergaard M, Kim J, Villadsen R, Fridriksdottir AJ, Rank F, Timmermans-Wielenga V, Langerød A, Børresen-Dale AL, Petersen OW, Rønnov-Jessen L.Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment. Am J Pathol 2010; 176: 1229-1240.
47.
Chen E, Li Q, Wang H, Zhang P, Zhao X, Yang F, Yang J. MiR-32 promotes tumorigenesis of colorectal cancer by targeting BMP5. Biomed Pharmacother 2018; 106: 1046-1051.
48.
Adnan Karim M, Samad A, Kumar Adhikari U, Ashraful Kader M, Kabir M, Aminul Islam M. A Multi-omics analysis of bone morphogenetic protein 5 (BMP5) mRNA expression and clinical prognostic outcomes in different cancers using 4 bioinformatics approaches 5. Int J Mol Sci [Internet] 2019; 20. Available from: www.mdpi.com/journal/ijms.
49.
Muhammad BA, Almozyan S, Babaei-Jadidi R, Onyido EK, Saadeddin A, Kashfi SH, Spencer-Dene B, Ilyas M, Lourdusamy A, Behrens A, Nateri AS. FLYWCH1, a novel suppressor of nuclear beta-catenin, regulates migration and morphology in colorectal cancer. Mol Cancer Res 2018; 16: 1977-1990.
50.
He H, Chen E, Lei L, Yan B, Zhao X, Zhu Z, Li Q, Zhang P, Zhang W, Xing J, Du L, Dong J, Yang J. Alteration of the tumor suppressor SARDH in sporadic colorectal cancer: a functional and transcriptome profiling-based study. Mol Carcinog 2019; 58: 957-966.
51.
Ren W, Chen S, Liu G, Wang X, Ye H, Xi Y. TUSC7 acts as a tumor suppressor in colorectal cancer. Am J Transl Res 2017; 9: 4026-4035.
52.
Xu J, Zhang R, Zhao J. The novel long noncoding RNA TUSC7 inhibits proliferation by sponging MiR-211 in colorectal cancer. Cell Physiol Biochem 2017; 41: 635-644.
53.
Zhang H, Song Y, Yang C, Wu X. Overexpression of lncRNA TUSC7 reduces cell migration and invasion in colorectal cancer. Oncol Rep 2019; 41: 3386-3392.
54.
Mauviel A, Nallet-Staub F, Varelas X. Integrating developmental signals: a Hippo in the (path)way. Oncogene 2012; 31: 1743-1756.
55.
Rybarczyk A, Wierzbicki P, Kowalczyk A, Kmieć Z. Role of the Hippo pathway in cell proliferation and organ size control. Disorders of the pathway in cancer diseases. Postepy Hig Med Dosw 2014; 68: 504-516.
56.
Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008; 39: 1582-1589.
57.
Iwasa H, Jiang X, Hata Y. RASSF6: the putative tumor suppressor of the RASSF family. Cancers (Basel) 2015; 7: 2415-2426.
58.
Chen E, Yang F, He H, Lei L, Liu R, Du L, Dong J, Wang M, Yang J. Decreased level of RASSF6 in sporadic colorectal cancer and its anti-tumor effects both in vitro and in vivo. Oncotarget 2016; 7: 19813-19823.
59.
Zhou R, Qiu L, Liu X, Ling L, Li N, Zhou K, Sun J, Yan J, Tan C, Huang X, Han L, Yin L, Xiao G, Liu L. RASSF6 downregulation promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal cancer. Oncotarget 2017; 8: 55162-55175.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
